RecruitingPhase 1NCT05687123
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Studying Neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Nikolaos TrikalinosYale University Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (10)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Memorial Hospital East, Shiloh, Illinois, United States
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Siteman Cancer Center-South County, St Louis, Missouri, United States
- Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05687123 on ClinicalTrials.govOther trials for Neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07273409Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or NotUppsala University
- ENROLLING BY INVITATIONPHASE2NCT07121478Patients With High-grade Pancreatic Neuroendocrine TumorsNational Cancer Center, Korea
- RECRUITINGPHASE2, PHASE3NCT06943755Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsExelixis
- RECRUITINGPHASE1NCT06663072Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsUniversity of Chicago
- ACTIVE NOT RECRUITINGNCT06406387ATRX/DAXX in EUS-FNB Specimens of Pan-NETsAzienda Ospedaliera Universitaria Integrata Verona
- RECRUITINGNCT06121622Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine TumoursIRCCS San Raffaele
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06148636A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsDavid Bushnell
- RECRUITINGPHASE2NCT05997056Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsAadi Bioscience, Inc.